A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 10, 2007, Pages 744-749

  Kim, Seong Geun ^a   Oh, Sung Yong ^a   Kwon, Hyuk Chan ^a   Lee, Suee ^a   Kim, Jung Hwan ^a   Kim, Sung Hyun ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Advanced gastric cancer; Irinotecan; Low dose leucovorin

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; SALVAGE THERAPY; STOMACH NEOPLASMS; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36248985703     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym103     Document Type: Article

References (26)

1. Bae JM, Park JG. Annual report of the Korea Central Cancer Registry Program 2000: Based on registered data from 131 hospitals. Cancer Res Treat 2002;34:77-83.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA cancer J Clin 2005;55:74-108.
3. Cuschieri A, Weeden S, Tielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer; long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522-30.
4. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer, drugs 1996;7:137-49.
5. Katpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach, in DeVita VT, Hellman S, Rosenberg SA. Cancer; Principles and Practice on Oncology (6th edn). Philadelphia, PA: Lippincott, Williams & Wilkins, 2001;1092-126.
6. Wilson D, Hillery L, Geh JI, Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005;17:81-90.
7. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin Oncol 1991;9:827-31.
8. Vanhoefer U, Rougier P, Wilke H, Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, duorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
9. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80: 269-72.
10. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49: 5077-82.
11. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
12. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer: CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8.
13. Boku N, Ohtsu A, Shimada Y, Shinto K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
14. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophagealgastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 2004;15:1773-81.
15. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a bi-weekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study FFCD, 9803. J Clin Oncol 2004;22:4319-28.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
18. Ducreux M, Ychou M, Şeitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-08.
19. Jager E, Heike M, Bernhard H, Klein O, Bernhard G, Lantz D, et al. weekly bigh-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. Study group for palliative treatment of metastatic colorectal cancer study protocol 1. J Clin Oncol 1996;14: 2274-9.
20. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthlyhigh dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French intergroup study. J Clin Oncol 1997;15:808-15.
21. Ducreaux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, et al. Randomized trial comparing three different schedules of infusional 5FU and raltitrexed alone in first line metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive 9601 trial. Ann Oncol 2002;13(Suppl 5):71.
22. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A Phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336-41.
23. Back JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, et al. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: A multicenter phase II study. J Korean Med Sci 2005;20:966-70.
24. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64-9.
25. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, et al. Salvage chemotherapy with irinoteçan, 5-fluorouracil and leucovorin for taxane-and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 2005;92:1850-4.
26. Chung JH, Bae YZ, Kim SH, Moon CH, Chung JY, Kwon HC, et al. Salvage treatment of advanced gastric cancer using FEP (5-FU, etoposide, cisplatin) combination chemotherapy. Cancer Res Treat 2002;34:382-7.